801-2, Jindong Mansion, No. 536 Xueshi Road, Yinzhou, Ningbo 315100, P.R.China
Home ProductsActive Pharmaceutical Ingredients

Dasabuvir Pharmaceutically Active Compounds 1132935-63-7 Anti Hepatitis C Virus

Dasabuvir Pharmaceutically Active Compounds 1132935-63-7 Anti Hepatitis C Virus

Dasabuvir Pharmaceutically Active Compounds 1132935-63-7 Anti Hepatitis C Virus

Product Details:

Place of Origin: China
Brand Name: Newlystar
Model Number: In - house

Payment & Shipping Terms:

Minimum Order Quantity: 10kg
Price: Negotiation
Packaging Details: Tin
Delivery Time: 30days
Supply Ability: One ton per month
Contact Now
Detailed Product Description
Product: Dasabuvir API CAS: 1132935-63-7
Purity: NTL 98.0% Standard: In - House
Usage: Anti Hepatitis C Virus

Dasabuvir Pharmaceutically Active Compounds 1132935-63-7 Anti Hepatitis C Virus

 

 

Dasabuvir API

CAS: 1132935-63-7

Purity: NTL 98.0%

 

Description :

Dasabuvir is an antiviral drug used for the treatment of hepatitis C virus (HCV) infection. As a Non-Nucleoside NS5B Polymerase Inhibitor, dasabuvir functions by inhibiting Nonstructural Protein 5B (NS5B), an RNA-dependent RNA polymerase required for viral replication of Hepatitis C Virus. By binding to NS5b outside of the active site of the enzyme, dasabuvir induces a conformational change thereby preventing further elongation of the nascent viral genome. A limitation of binding outside of the active site is that these binding sites are poorly preserved across the viral genotypes. This results in a limited potential for cross-genotypic activity and increased potential for development of resistance. Dasabuvir is therefore limited to treating genotypes 1a and 1b, and must be used in combination with other antiviral products. Dasabuvir is currently approved for use in the management of Hepatitis C infection in combination with ombitasvir, paritaprevir, and ritonavir as the combination product Viekira Pak.

 

Indication :

Dasabuvir, in combination with ombitasvir, paritaprevir, and ritonavir (as Viekira Pak) is indicated for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection including those with compensated cirrhosis.

 

Pharmacodynamics :

At concentrations approximately 6, 1.8 and 2 times the therapeutic concentrations of paritaprevir, ombitasvir, and dasabuvir, the combination did not prolong QTc to any clinically relevant extent.


Mechanism of action :

Dasabuvir is a non-nucleoside inhibitor of the HCV RNA-dependent RNA polymerase encoded by the NS5B gene, which is essential for replication of the viral genome. Based on drug resistance mapping studies of HCV genotypes 1a and 1b, dasabuvir targets the palm domain of the NS5B polymerase, and is therefore referred to as a non-nucleoside NS5B-palm polymerase inhibitor. The EC50 values of dasabuvir against genotype 1a-H77 and 1b-Con1 strains in HCV replicon cell culture assays were 7.7 nM and 1.8 nM, respectively. (Viekira Pak Product Monograph) By binding to NS5b outside of the active site of the enzyme, dasabuvir induces a conformational change thereby preventing further elongation of the nascent viral genome. A limitation of binding outside of the active site is that these binding sites are poorly preserved across the viral genotypes. This results in a limited potential for cross-genotypic activity and increased potential for development of resistance. Dasabuvir is therefore limited to treating genotypes 1a and 1b, and must be used in combination with other antiviral products.

Contact Details
Newlystar (Ningbo) Medtech Co.,Ltd.

Contact Person: Luke Liu

Send your inquiry directly to us (0 / 3000)